

Reviews in Cardiovascular Medicine Subject Index to Volume 4

Abciximab

Best of TCT 2002 [Meeting Review]. 4(2):100-106.

Acute coronary syndromes

de Lemos JA, Morrow DA. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. 4(suppl 4):S37-S46.

Jacobs AK. Statin therapy and timing [Literature Review]. 4(4):262-263.

Jesse RL. Neurohormonal regulation and the overlapping pathology between heart failure and acute coronary syndromes. 4(suppl 4):S29-S36.

McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. 4(2):72-80.

McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. 4(suppl 4):S13-S19.

Acute decompensated heart failure

Emerman C. Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy. 4(suppl 7):S13-S20.

Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE™): opportunities to improve care of patients hospitalized with ADHF. 4(suppl 7):S21-S30.

Acute ischemic stroke

Connors JJ. Interventional stroke therapy: the potential benefit of direct intra-arterial infusion. 3(suppl 2):S92-S99.

Acute limb ischemia

Katzen BT. Clinical diagnosis and prognosis of acute limb ischemia. 3(suppl 2):S2-S6.

Ouriel K. Comparison of surgical and thrombolytic treatment of peripheral arterial disease. 3(suppl 2):S7-S16.

Acute myocardial infarction

Fonarow GC. The role of in-hospital initiation of cardiovascular protective therapies to improve treatment rates and clinical outcomes. 4(suppl 3):S37-S46.

Fonarow GC, Abraham WT, Cannon CP, et al. Role of β -blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction: The Post-Myocardial Infarction Guideline Committee. 4(suppl 3):S54-S59.

Lepor NE. The prognostic value of renal function in patients with congestive heart failure and acute myocardial infarction [Literature Review]. 4(3):192-194.

Wachsmann DE, Jacobs AK. Paradoxical coronary embolism: a rare cause of acute myocardial infarction. 4(2):107-111.

Acute renal failure

McCullough PA. Beyond serum creatinine: defining the patient with renal insufficiency and why? 4(suppl 1):S2-S6.

McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. 4(suppl 5):S3-S9.

Mathur VS. The role of the DA₁ receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. 4(suppl 1):S35-S40.

Sheinbaum R, Ignacio C, Safi HJ, Estrera A. Contemporary strategies to preserve renal function during cardiac and vascular surgery. 4(suppl 1):S21-S28.

ADHERE

Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.

Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE™): opportunities to improve care of patients hospitalized with ADHF. 4(suppl 7):S21-S30.

ALLHAT

Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.

ANBP2

Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.

Aneurysmal rupture

Kirkpatrick JN, Ring M, Lang RM. Expanding the differential diagnosis of hemoptysis:

mycotic aortic aneurysms. 4(3):180-183.

Angina

Gersh BJ. Coronary revascularization for angina pectoris in the elderly [Literature Review]. 4(1):55-58.

Angiogenesis

Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.

Angiography

Fearon WF, Yeung AC. Evaluating intermediate coronary lesions in the cardiac catheterization laboratory. 4(1):1-7.

Angioplasty

McCullough PA. Beyond serum creatinine: defining the patient with renal insufficiency and why? 4(suppl 1):S2-S6.

Angiotensin

Abraham WT. Diabetes, hypertension, and renal insufficiency in post-myocardial infarction cardiovascular risk. 4(suppl 3):S30-S36.

Angiotensin-converting enzyme inhibitors

Fonarow GC. The management of the diabetic patient with prior cardiovascular events. 4(suppl 6):S38-S49.

Fonarow GC. The role of in-hospital initiation of cardiovascular protective therapies to improve treatment rates and clinical outcomes. 4(suppl 3):S37-S46.

Lepor NE. Angiotensin receptor blockers versus angiotensin converting enzyme inhibitors and the treatment of hypertension in diabetic patients [Literature Review]. 4(2):118-121.

Miller LW. Limitations of current medical therapies for the treatment of heart failure. 4(suppl 2):S21-S29.

Udelson JE, Patten RD, Konstam MA. New concepts in post-infarction ventricular remodeling. 4(suppl 3):S3-S12.

Angiotensin receptor blockers

Lepor NE. Angiotensin receptor blockers versus angiotensin converting enzyme

- inhibitors and the treatment of hypertension in diabetic patients [Literature Review]. 4(2):118-121.
- Miller LW. Limitations of current medical therapies for the treatment of heart failure. 4(suppl 2):S21-S29.
- Antiarrhythmic drugs**
- Prystowsky EN. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator. 4(suppl 2):S47-S54.
- Anticoagulation**
- Lepor NE. Recent study findings on predicting and improving outcomes [Literature Review]. 4(3):188-191.
- Antiplatelet therapy**
- Doyle J, Creager MA. Pharmacotherapy and behavioral intervention for peripheral arterial disease. 4(1):18-24.
- Fonarow GC. The role of in-hospital initiation of cardiovascular protective therapies to improve treatment rates and clinical outcomes. 4(suppl 3):S37-S46.
- Aortobronchial fistulas**
- Kirkpatrick JN, Ring M, Lang RM. Expanding the differential diagnosis of hemoptysis: mycotic aortic aneurysms. 4(3):180-183.
- Aortic dissection**
- Naqvi TZ, Zaky JW, Raissi SS. Transesophageal echocardiographic evaluation of perioperative systolic murmur in aortic pathology. 4(2):112-116.
- ARCHER**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Arteriogram**
- Connors JJ. Interventional stroke therapy: the potential benefit of direct intra-arterial infusion. 3(suppl 2):S92-S99.
- ASCOT**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- ASSENT III Plus**
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Asymptomatic left ventricular dysfunction**
- Fonarow GC, Horwich TB. Prevention of heart failure: effective strategies to combat the growing epidemic. 4(1):8-17.
- Atherosclerosis**
- Doyle J, Creager MA. Pharmacotherapy and behavioral intervention for peripheral arterial disease. 4(1):18-24.
- Katzen BT. Clinical diagnosis and prognosis of acute limb ischemia. 3(suppl 2):S2-S6.
- McCullough PA. Beyond serum creatinine: defining the patient with renal insufficiency and why? 4(suppl 1):S2-S6.
- Shah PK. Combining coronary calcium scores and c-reactive protein levels to predict cardiovascular events [Literature Review]. 4(2):117-118.
- Shah PK. Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis. 4(3):136-141.
- Atrial fibrillation**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Atrial septal defect**
- Wachsman DE, Jacobs AK. Paradoxical coronary embolism: a rare cause of acute myocardial infarction. 4(2):107-111.
- Autologous skeletal myoblast transplantation**
- Yeung AC. Feasibility and safety of skeletal myoblast transplantation [Literature Review]. 4(4):261-262.
- Avasimibe**
- Shah PK. Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis. 4(3):136-141.
- Axillary-subclavian venous thrombosis**
- Meissner MH. Axillary-subclavian venous thrombosis. 3(suppl 2):S76-S83.
- Bacterial organisms**
- Kirkpatrick JN, Ring M, Lang RM. Expanding the differential diagnosis of hemoptysis: mycotic aortic aneurysms. 4(3):180-183.
- Balloon angioplasty**
- Best of TCT 2002 [Meeting Review]. 4(2):100-106.
- Beta-blockade**
- Fonarow GC. The management of the diabetic patient with prior cardiovascular events. 4(suppl 6):S38-S49.
- Beta-blockers**
- Abraham WT. Diabetes, hypertension, and renal insufficiency in post-myocardial infarction cardiovascular risk. 4(suppl 3):S30-S36.
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Borrello F, Beahan M, Klein L, Gheorghide M. Reappraisal of β -blocker therapy in the acute and chronic post-myocardial infarction period. 4(suppl 3):S13-S24.
- Fonarow GC. The role of in-hospital initiation of cardiovascular protective therapies to improve treatment rates and clinical outcomes. 4(suppl 3):S37-S46.
- Fonarow GC, Abraham WT, Cannon CP, et al. Role of β -blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction: The Post-Myocardial Infarction Guideline Committee. 4(suppl 3):S54-S59.
- Miller LW. Limitations of current medical therapies for the treatment of heart failure. 4(suppl 2):S21-S29.
- Sackner-Bernstein JD. New evidence from the CAPRICORN trial: the role of carvedilol in high-risk, post-myocardial infarction patients. 4(suppl 3):S25-S29.
- Udelson JE, Patten RD, Konstam MA. New concepts in post-infarction ventricular remodeling. 4(suppl 3):S3-S12.
- Yoerger DM, Weyman AE. Hypertrophic obstructive cardiomyopathy: mechanism of obstruction and response to therapy. 4(4):199-215.
- Bivalirudin**
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Biventricular pacing**
- Abraham WT. Cardiac resynchronization therapy: a review of clinical trials and criteria for identifying the appropriate patient. 4(suppl 2):S30-S37.
- Kass DA. Ventricular resynchronization: pathophysiology and identification of responders. 4(suppl 2):S3-S13.
- Leon AR. Practical issues in cardiac resynchronization therapy device implantation. 4(3):142-149.
- B-type natriuretic peptide**
- de Lemos JA, Morrow DA. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. 4(suppl 4):S37-S46.
- Emmerman C. Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy. 4(suppl 7):S13-S20.
- Fonarow GC, Horwich TB. Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure. 4(suppl 4):S20-S28.
- Gibler WB, Blomkalns AL, Collins SP. Evaluation of chest pain and heart failure in the emergency department: impact of multimarker strategies and b-type natriuretic peptide. 4(suppl 4):S47-S55.
- Jesse RL. Neurohormonal regulation and the overlapping pathology between heart failure and acute coronary syndromes. 4(suppl 4):S29-S36.
- Lepor NE. Recent study findings on predicting and improving outcomes [Literature Review]. 4(3):188-191.
- Maisel AS, McCullough PA. Cardiac natriuretic peptides: a proteomic window to cardiac function and clinical management. 4(suppl 4):S3-S12.
- McCullough PA, Joseph K, Mathur VS. Diagnostic and therapeutic utility of b-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. 4(suppl 7):S3-S12.
- McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. 4(2):72-80.
- McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. 4(suppl 4):S13-S19.
- CADILLAC**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.

Calcium channel blockers

Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.

Miller LW. Limitations of current medical therapies for the treatment of heart failure. 4(suppl 2):S21-S29.

Shah PK. The calcium channel blocker lacidipine slows the progression of carotid atherosclerosis [Literature Review]. 4(3):191-192.

Yoerger DM, Weyman AE. Hypertrophic obstructive cardiomyopathy: mechanism of obstruction and response to therapy. 4(4):199-215.

Cardiac asynchrony

Leon AR. Practical issues in cardiac resynchronization therapy device implantation. 4(3):142-149.

Cardiac catheterization

Erdogan A, Davidson CJ. Recent clinical trials of iodixanol. 4(suppl 5):S43-S50.

Cardiac dyssynchrony

Leon AR. Cardiac resynchronization therapy devices: patient management and follow-up strategies. 4(suppl 2):S38-S46.

Cardiac myocyte hypertrophy

Francis GS, Tang WHW. Pathophysiology of congestive heart failure. 4(suppl 2):S14-S20.

Cardiac resynchronization therapy

Abraham WT. Cardiac resynchronization therapy: a review of clinical trials and criteria for identifying the appropriate patient. 4(suppl 2):S30-S37.

Kass DA. Ventricular resynchronization: pathophysiology and identification of responders. 4(suppl 2):S3-S13.

Leon AR. Practical issues in cardiac resynchronization therapy device implantation. 4(3):142-149.

Prystowsky EN. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator. 4(suppl 2):S47-S54.

Cardiac surgery

Nussmeier NA. Improving perioperative outcomes in patients with end-stage heart failure. 4(suppl 1):S29-S34.

Cardiac troponins

de Lemos JA, Morrow DA. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. 4(suppl 4):S37-S46.

Fonarow GC, Horwich TB. Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure. 4(suppl 4):S20-S28.

Gibler WB, Blomkalns AL, Collins SP. Evaluation of chest pain and heart failure in the emergency department: impact of multimer strategies and b-type natriuretic peptide. 4(suppl 4):S47-S55.

Cardiac tumor

Schoondyke JW, Burrell JW, Shabaneh B, et

al. Papillary fibroelastoma involving the left ventricular wall. 4(3):184-187.

CARDINAL

Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.

Cardiomyopathy

Best of TCT 2002 [Meeting Review]. 4(2):100-106.

Yeung AC. Feasibility and safety of skeletal myoblast transplantation [Literature Review]. 4(4):261-262.

Cardiovascular disease

Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.

McCullough PA. Beyond serum creatinine: defining the patient with renal insufficiency and why? 4(suppl 1):S2-S6.

McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. 4(suppl 5):S3-S9.

Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. 4(suppl 6):S11-S18.

Shah PK. Does the lysyl oxidase gene *Lox* play a critical role in cardiovascular disease? [Literature Review]. 4(2):121.

Zarich SW. Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors. 4(suppl 6):S19-S28.

Cardiovascular events

Fonarow GC. The management of the diabetic patient with prior cardiovascular events. 4(suppl 6):S38-S49.

Cardiovascular surgery

Sheinbaum R, Ignacio C, Safi HJ, Estrera A. Contemporary strategies to preserve renal function during cardiac and vascular surgery. 4(suppl 1):S21-S28.

Carotid artery disease

Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.

Carotid atherosclerosis

Shah PK. The calcium channel blocker lacidipine slows the progression of carotid atherosclerosis [Literature Review]. 4(3):191-192.

Carotid endarectomy

Ouriel K, Yadav JS. The role of stents in patients with carotid disease. 4(2):61-67.

Carotid stenting

Ouriel K, Yadav JS. The role of stents in patients with carotid disease. 4(2):61-67.

Catheter-directed thrombolysis

Comerota AJ. Quality-of-life improvement using thrombolytic therapy for iliofemoral deep venous thrombosis. 3(suppl 2):S61-S67.

Meissner MH. Thrombolytic therapy for acute deep vein thrombosis and the venous registry. 3(suppl 2):S53-S60.

Chest pain

Gibler WB, Blomkalns AL, Collins SP. Evaluation of chest pain and heart failure in

the emergency department: impact of multimer strategies and b-type natriuretic peptide. 4(suppl 4):S47-S55.

Cholesterol

Lepor NE. Children and cholesterol [Literature Review]. 4(1):54.

Shah PK. Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis. 4(3):136-141.

Chronic kidney disease

Best of TCT 2003 [Meeting Review]. 4(4):237-249.

Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.

Keeley EC, McCullough PA. Coronary revascularization in patients with end-stage renal disease: risks, benefits, and optimal strategies. 4(3):125-130.

McCullough PA. Beyond serum creatinine: defining the patient with renal insufficiency and why? 4(suppl 1):S2-S6.

McCullough PA, Joseph K, Mathur VS. Diagnostic and therapeutic utility of b-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. 4(suppl 7):S3-S12.

McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. 4(suppl 5):S3-S9.

Class effects

Sackner-Bernstein JD. New evidence from the CAPRICORN trial: the role of carvedilol in high-risk, post-myocardial infarction patients. 4(suppl 3):S25-S29.

Clinical pathways

Cannon CP. Critical pathways for acute myocardial infarction. 4(suppl 3):S47-S53.

Clopidogrel

Best of TCT 2002 [Meeting Review]. 4(2):100-106.

Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.

Color Doppler echocardiography

Naqvi TZ. Diastolic function assessment incorporating new techniques in Doppler echocardiography. 4(2):81-99.

COMET

Fonarow GC. Carvedilol is superior to metoprolol for mortality reduction in heart failure [Literature Review]. 4(4):260-261.

COMPANION

Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.

Congestive heart failure

Gibler WB, Blomkalns AL, Collins SP. Evaluation of chest pain and heart failure in the emergency department: impact of multimer strategies and b-type natriuretic peptide. 4(suppl 4):S47-S55.

Jesse RL. Neurohormonal regulation and the overlapping pathology between heart failure and acute coronary syndromes. 4(suppl 4):S29-S36.

- Leon AR. Cardiac resynchronization therapy devices: patient management and follow-up strategies. 4(suppl 2):S38-S46.
- Leon AR. Practical issues in cardiac resynchronization therapy device implantation. 4(3):142-149.
- Lepor NE. The prognostic value of renal function in patients with congestive heart failure and acute myocardial infarction [Literature Review]. 4(3):192-194.
- Maisel AS, McCullough PA. Cardiac natriuretic peptides: a proteomic window to cardiac function and clinical management. 4(suppl 4):S3-S12.
- McCullough PA, Joseph K, Mathur VS. Diagnostic and therapeutic utility of b-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. 4(suppl 7):S3-S12.
- McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. 4(2):72-80.
- Naqvi TZ. Diastolic function assessment incorporating new techniques in Doppler echocardiography. 4(2):81-99.
- CONTAK CD**
- Abraham WT. Cardiac resynchronization therapy: a review of clinical trials and criteria for identifying the appropriate patient. 4(suppl 2):S30-S37.
- CONTRAST**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Contrast-induced nephropathy**
- Best of TCT 2003 [Meeting Review]. 4(4):237-249.
- Lepor NE. A review of pharmacologic interventions to prevent contrast-induced nephropathy. 4(suppl 5):S34-S42.
- Lepor NE. Recent study findings on predicting and improving outcomes [Literature Review]. 4(3):188-191.
- McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. 4(suppl 5):S3-S9.
- Nikolsky E, Mehran R. Understanding the consequences of contrast-induced nephropathy. 4(suppl 5):S10-S18.
- Rudnick MR, Goldfarb S. Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. 4(suppl 5):S28-S33.
- Contrast media**
- Erdogan A, Davidson CJ. Recent clinical trials of iodoxanol. 4(suppl 5):S43-S50.
- Nikolsky E, Aymong ED, Dargas G, Mehran R. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. 4(suppl 1):S7-S14.
- Contrast toxicity**
- Brinker J. What every cardiologist should know about intravascular contrast. 4(suppl 5):S19-S27.
- COOL-MI**
- Best of TCT 2003 [Meeting Review]. 4(4):237-249.
- Coronary artery bypass graft**
- Best of TCT 2002 [Meeting Review]. 4(2):100-106.
- Coronary artery calcification**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Coronary artery disease**
- Keeley EC, McCullough PA. Coronary revascularization in patients with end-stage renal disease: risks, benefits, and optimal strategies. 4(3):125-130.
- Coronary calcium**
- Mazur W, McCracken M, Kereiakes DJ. Coronary calcium and c-reactive protein: another tip of the iceberg [Literature Review]. 4(3):194-196.
- Coronary flow reserve**
- Fearon WF, Yeung AC. Evaluating intermediate coronary lesions in the cardiac catheterization laboratory. 4(1):1-7.
- Coronary heart disease**
- Vogel RA. The changing view of hormone replacement therapy. 4(2):68-71.
- Coronary lesions**
- Fearon WF, Yeung AC. Evaluating intermediate coronary lesions in the cardiac catheterization laboratory. 4(1):1-7.
- Coronary revascularization**
- Gersh BJ. Coronary revascularization for angina pectoris in the elderly [Literature Review]. 4(1):55-58.
- Coronary sinus**
- Leon AR. Practical issues in cardiac resynchronization therapy device implantation. 4(3):142-149.
- COURT**
- Best of TCT 2003 [Meeting Review]. 4(4):237-249.
- C-reactive protein**
- de Lemos JA, Morrow DA. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. 4(suppl 4):S37-S46.
- Mazur W, McCracken M, Kereiakes DJ. Coronary calcium and c-reactive protein: another tip of the iceberg [Literature Review]. 4(3):194-196.
- Shah PK. Combining coronary calcium scores and c-reactive protein levels to predict cardiovascular events [Literature Review]. 4(2):117-118.
- Creatine kinase**
- de Lemos JA, Morrow DA. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. 4(suppl 4):S37-S46.
- Creatine kinase-MB**
- Gibler WB, Blomkalns AL, Collins SP. Evaluation of chest pain and heart failure in the emergency department: impact of multimer strategies and b-type natriuretic peptide. 4(suppl 4):S47-S55.
- Creatinine**
- Nikolsky E, Mehran R. Understanding the consequences of contrast-induced nephropathy. 4(suppl 5):S10-S18.
- CREDO**
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Critical pathways**
- Cannon CP. Critical pathways for acute myocardial infarction. 4(suppl 3):S47-S53.
- Deep venous thrombosis**
- Meissner MH. Thrombolytic therapy for acute deep vein thrombosis and the venous registry. 3(suppl 2):S53-S60.
- Olin JW. Pulmonary embolism. 3(suppl 2):S68-S75.
- DELIVER**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Dementia**
- Weber MA. The effects on dementia of long-term treatment of hypertension [Literature Review]. 4(3):197-198.
- Diabetes mellitus**
- Abraham WT. Diabetes, hypertension, and renal insufficiency in post-myocardial infarction cardiovascular risk. 4(suppl 3):S30-S36.
- Best of TCT 2003 [Meeting Review]. 4(4):237-249.
- Edelman SV. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors. 4(suppl 6):S29-S37.
- Fonarow GC. The management of the diabetic patient with prior cardiovascular events. 4(suppl 6):S38-S49.
- Fonarow GC, Horwich TB. Prevention of heart failure: effective strategies to combat the growing epidemic. 4(1):8-17.
- Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. 4(suppl 6):S11-S18.
- DIAL**
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Dialysis**
- McCullough PA. Beyond serum creatinine: defining the patient with renal insufficiency and why? 4(suppl 1):S2-S6.
- McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. 4(suppl 5):S3-S9.
- Nikolsky E, Aymong ED, Dargas G, Mehran R. Radiocontrast nephropathy: identifying the high-risk patient and the implications

- of exacerbating renal function. 4(suppl 1): S7-S14.
- Diastolic dysfunction**
Naqvi TZ. Diastolic function assessment incorporating new techniques in Doppler echocardiography. 4(2):81-99.
- Digitalis**
Miller LW. Limitations of current medical therapies for the treatment of heart failure. 4(suppl 2):S21-S29.
- Dilated cardiomyopathy**
Francis GS, Tang WHW. Pathophysiology of congestive heart failure. 4(suppl 2):S14-S20.
- Doppler tissue imaging**
Naqvi TZ. Diastolic function assessment incorporating new techniques in Doppler echocardiography. 4(2):81-99.
- Doppler ultrasonography**
Katzen BT. Clinical diagnosis and prognosis of acute limb ischemia. 3(suppl 2):S2-S6.
- Drug-eluting stents**
Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
Best of TCT 2002 [Meeting Review]. 4(2): 100-106.
Best of TCT 2003 [Meeting Review]. 4(4): 237-249.
- Dyslipidemia**
Zarich SW. Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors. 4(suppl 6): S19-S28.
- Dyspnea**
Gibler WB, Blomkalns AL, Collins SP. Evaluation of chest pain and heart failure in the emergency department: impact of multimer strategies and b-type natriuretic peptide. 4(suppl 4):S47-S55.
Maisel AS, McCullough PA. Cardiac natriuretic peptides: a proteomic window to cardiac function and clinical management. 4(suppl 4):S3-S12.
- Echocardiography**
Kass DA. Ventricular resynchronization: pathophysiology and identification of responders. 4(suppl 2):S3-S13.
Leon AR. Cardiac resynchronization therapy devices: patient management and follow-up strategies. 4(suppl 2):S38-S46.
Naqvi TZ. Diastolic function assessment incorporating new techniques in Doppler echocardiography. 4(2):81-99.
- e-Hepatocyte growth factor**
Best of TCT 2003 [Meeting Review]. 4(4): 237-249.
- Elastase**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Electrocardiogram**
Riaz K, McCullough PA. Fatal case of delayed repolarization due to cocaine abuse and global ischemia. 4(1):47-53.
- Embolic protection**
Ouriel K, Yadav JS. The role of stents in patients with carotid disease. 4(2):61-67.
- End-stage renal disease**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
Keeley EC, McCullough PA. Coronary revascularization in patients with end-stage renal disease: risks, benefits, and optimal strategies. 4(3):125-130.
- ENDEAVOR-I**
Best of TCT 2003 [Meeting Review]. 4(4): 237-249.
- Endometrial cancer**
Vogel RA. The changing view of hormone replacement therapy. 4(2):68-71.
- Endothelial cells**
Best of TCT 2003 [Meeting Review]. 4(4): 237-249.
- Endothelium**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Enoxaparin**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- EPHESUS**
Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Everolimus**
Best of TCT 2003 [Meeting Review]. 4(4): 237-249.
- Ezetimibe**
Shah PK. Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis. 4(3):136-141.
- FACIT**
Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Fenoldopam**
Lepor NE. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and n-acetylcysteine. 4(suppl 1):S15-S20.
Mathur VS. The role of the DA₁ receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. 4(suppl 1):S35-S40.
Sheinbaum R, Ignacio C, Safi HJ, Estrera A. Contemporary strategies to preserve renal function during cardiac and vascular surgery. 4(suppl 1):S21-S28.
- Fibrin**
Deitcher SR, Jaff MR. Pharmacologic and clinical characteristics of thrombolytic agents. 3(suppl 2):S25-S33.
- Fibrin degradation products**
Bell WR. Therapeutic agents—pharmacokinetics and pharmacodynamics. 3(suppl 2): S34-S44.
- Fibrinolysis**
Best of TCT 2002 [Meeting Review]. 4(2):100-106.
Deitcher SR, Jaff MR. Pharmacologic and clinical characteristics of thrombolytic agents. 3(suppl 2):S25-S33.
- Fibrinolytic system**
Bell WR. Therapeutic agents—pharmacokinetics and pharmacodynamics. 3(suppl 2): S34-S44.
- Fibrinolytic therapy**
Young JJ, Kereiakes DJ. Pharmacologic reperfusion strategies for the treatment of ST-segment elevation myocardial infarction. 4(4):216-227.
- FIRE**
Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Flow enhancement**
Connors JJ. Interventional stroke therapy: the potential benefit of direct intra-arterial infusion. 3(suppl 2):S92-S99.
- Fractional flow reserve**
Fearon WF, Yeung AC. Evaluating intermediate coronary lesions in the cardiac catheterization laboratory. 4(1):1-7.
- Fragment X**
Deitcher SR, Jaff MR. Pharmacologic and clinical characteristics of thrombolytic agents. 3(suppl 2):S25-S33.
- FUTURE II**
Best of TCT 2003 [Meeting Review]. 4(4): 237-249.
- Glomerular filtration rate**
Lepor NE. A review of pharmacologic interventions to prevent contrast-induced nephropathy. 4(suppl 5):S34-S42.
Nikolsky E, Mehran R. Understanding the consequences of contrast-induced nephropathy. 4(suppl 5):S10-S18.
- Glucose intolerance**
Zarich SW. Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors. 4(suppl 6): S19-S28.
- Glycemic control**
Zarich SW. Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors. 4(suppl 6): S19-S28.
- Glycoprotein IIb/IIIa antagonist**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Glycoprotein IIb/IIIa inhibition**
Young JJ, Kereiakes DJ. Pharmacologic reperfusion strategies for the treatment of ST-segment elevation myocardial infarction. 4(4):216-227.
- Glycosylated hemoglobin**
Edelman SV. The role of the thiazolidinediones in the practical management of

- patients with type 2 diabetes and cardiovascular risk factors. 4(suppl 6):S29-S37.
- Guggulsterone**
Shah PK. Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis. 4(3):136-141.
- Heart-assist device**
Nussmeier NA. Improving perioperative outcomes in patients with end-stage heart failure. 4(suppl 1):S29-S34.
- Heart failure**
Abraham WT. Cardiac resynchronization therapy: a review of clinical trials and criteria for identifying the appropriate patient. 4(suppl 2):S30-S37.
Abraham WT. Diabetes, hypertension, and renal insufficiency in post-myocardial infarction cardiovascular risk. 4(suppl 3):S30-S36.
Fonarow GC. Carvedilol is superior to metoprolol for mortality reduction in heart failure [Literature Review]. 4(4):260-261.
Fonarow GC. The management of the diabetic patient with prior cardiovascular events. 4(suppl 6):S38-S49.
Fonarow GC, Horwich TB. Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure. 4(suppl 4):S20-S28.
Fonarow GC, Horwich TB. Prevention of heart failure: effective strategies to combat the growing epidemic. 4(1):8-17.
Francis GS, Tang WHW. Pathophysiology of congestive heart failure. 4(suppl 2):S14-S20.
Kass DA. Ventricular resynchronization: pathophysiology and identification of responders. 4(suppl 2):S3-S13.
McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. 4(suppl 4):S13-S19.
Miller LW. Limitations of current medical therapies for the treatment of heart failure. 4(suppl 2):S21-S29.
Nussmeier NA. Improving perioperative outcomes in patients with end-stage heart failure. 4(suppl 1):S29-S34.
Sackner-Bernstein JD. New evidence from the CAPRICORN trial: the role of carvedilol in high-risk, post-myocardial infarction patients. 4(suppl 3):S25-S29.
- Hemorrhage**
Ouriel K. Safety and efficacy of the various thrombolytic agents. 3(suppl 2):S17-S24.
- Hemodialysis access grafts**
Cynamon J, Pierpont CE. Thrombolysis for the treatment of thrombosed hemodialysis access grafts. 3(suppl 2):S84-S91.
- Hemolysis**
Khanna A, McCullough PA. Malignant hypertension presenting as hemolysis, thrombocytopenia, and renal failure. 4(4):255-259.
- Hemoptysis**
Kirkpatrick JN, Ring M, Lang RM. Expanding the differential diagnosis of hemoptysis: mycotic aortic aneurysms. 4(3):180-183.
- Heparin**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Hepatic lipase**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- HMG-CoA reductase inhibitors**
Shah PK. Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis. 4(3):136-141.
- Hormone replacement therapy**
Vogel RA. The changing view of hormone replacement therapy. 4(2):68-71.
- Hospitalization**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE™): opportunities to improve care of patients hospitalized with ADHF. 4(suppl 7):S21-S30.
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Hydration**
Lepor NE. A review of pharmacologic interventions to prevent contrast-induced nephropathy. 4(suppl 5):S34-S42.
- Hyperbaric oxygen therapy**
Best of TCT 2003 [Meeting Review]. 4(4):237-249.
- Hyperinsulinemia**
Goldstein BJ. Insulin resistance: from benign to type 2 diabetes mellitus. 4(suppl 6):S3-S10.
- Hyperlipidemia**
Lepor NE. Children and cholesterol [Literature Review]. 4(1):5-4.
- Hypertension**
Fonarow GC, Horwich TB. Prevention of heart failure: effective strategies to combat the growing epidemic. 4(1):8-17.
Khanna A, McCullough PA. Malignant hypertension presenting as hemolysis, thrombocytopenia, and renal failure. 4(4):255-259.
Lepor NE. Angiotensin receptor blockers versus angiotensin converting enzyme inhibitors and the treatment of hypertension in diabetic patients [Literature Review]. 4(2):118-121.
Mathur VS. The role of the DA₁ receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. 4(suppl 1):S35-S40.
Weber MA. The effects on dementia of long-term treatment of hypertension [Literature Review]. 4(3):197-198.
- Zarich SW. Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors. 4(suppl 6):S19-S28.
- Hypertrophic cardiomyopathy**
Yoerger DM, Weyman AE. Hypertrophic obstructive cardiomyopathy: mechanism of obstruction and response to therapy. 4(4):199-215.
- Hypoperfusion**
Holmes DR. Cardiogenic shock: a lethal complication of acute myocardial infarction. 4(3):131-135.
- Hypotension**
Holmes DR. Cardiogenic shock: a lethal complication of acute myocardial infarction. 4(3):131-135.
- Iliofemoral deep venous thrombosis**
Comerota AJ. Quality-of-life improvement using thrombolytic therapy for iliofemoral deep venous thrombosis. 3(suppl 2):S61-S67.
- IMPACT-HF**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Impaired fasting glucose**
Best of TCT 2003 [Meeting Review]. 4(4):237-249.
- Implantable cardioverter defibrillator**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
Prystowsky EN. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator. 4(suppl 2):S47-S54.
- Infarct-related artery patency**
Young JJ, Kereiakes DJ. Pharmacologic reperfusion strategies for the treatment of ST-segment elevation myocardial infarction. 4(4):216-227.
- INSTOR**
Connors JJ. Interventional stroke therapy: the potential benefit of direct intra-arterial infusion. 3(suppl 2):S92-S99.
- Insulin resistance**
Edelman SV. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors. 4(suppl 6):S29-S37.
Goldstein BJ. Insulin resistance: from benign to type 2 diabetes mellitus. 4(suppl 6):S3-S10.
Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. 4(suppl 6):S11-S18.
Shah A, Shannon RP. Insulin resistance in dilated cardiomyopathy. 4(suppl 6):S50-S57.
Watson KE, Horowitz BN, Matson G. Lipid abnormalities in insulin resistant states. 4(4):228-236.
- Insulin signaling**
Shah A, Shannon RP. Insulin resistance in dilated cardiomyopathy. 4(suppl 6):S50-S57.

Intermittent claudication

Doyle J, Creager MA. Pharmacotherapy and behavioral intervention for peripheral arterial disease. 4(1):18-24.

Intra-arterial thrombolysis

Connors JJ. Interventional stroke therapy: the potential benefit of direct intra-arterial infusion. 3(suppl 2):S92-S99.

Intravascular ultrasound

Fearon WF, Yeung AC. Evaluating intermediate coronary lesions in the cardiac catheterization laboratory. 4(1):1-7.

Intravenous hydration

Lepor NE. A review of contemporary prevention strategies for radioccontrast nephropathy: a focus on fenoldopam and n-acetylcysteine. 4(suppl 1):S15-S20.

INVEST

Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.

ISAR-COOL

Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.

ISAR-REACT

Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.

ISAR-SMART II

Best of TCT 2003 [Meeting Review]. 4(4):237-249.

Ischemia

Jesse RL. Neurohormonal regulation and the overlapping pathology between heart failure and acute coronary syndromes. 4(suppl 4):S29-S36.

Ischemic heart disease

Fonarow GC, Horwich TB. Prevention of heart failure: effective strategies to combat the growing epidemic. 4(1):8-17.

ISIS-4 Trial

Gersh BJ. Results from the magnesium in coronaries trial [Meeting Review]. 4(4):250-254.

Lambl's excrescence

Schoondyke JW, Burrell JW, Shabaneh B, et al. Papillary fibroelastoma involving the left ventricular wall. 4(3):184-187.

Left ventricular dysfunction

Fonarow GC, Abraham WT, Cannon CP, et al. Role of β -blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction: The Post-Myocardial Infarction Guideline Committee. 4(suppl 3):S54-S59.

Maisel AS, McCullough PA. Cardiac natriuretic peptides: a proteomic window to cardiac function and clinical management. 4(suppl 4):S3-S12.

Left ventricular function

Jesse RL. Neurohormonal regulation and the overlapping pathology between heart failure and acute coronary syndromes. 4(suppl 4):S29-S36.

Left ventricular outflow tract

Yoerger DM, Weyman AE. Hypertrophic obstructive cardiomyopathy: mechanism of obstruction and response to therapy. 4(4):199-215.

Left ventricular pacing

Kass DA. Ventricular resynchronization: pathophysiology and identification of responders. 4(suppl 2):S3-S13.

Left ventricular remodeling

Udelson JE, Patten RD, Konstam MA. New concepts in post-infarction ventricular remodeling. 4(suppl 3):S3-S12.

Limb ischemia

Doyle J, Creager MA. Pharmacotherapy and behavioral intervention for peripheral arterial disease. 4(1):18-24.

LIMIT-2

Gersh BJ. Results from the magnesium in coronaries trial [Meeting Review]. 4(4):250-254.

Lipolysis

Shah A, Shannon RP. Insulin resistance in dilated cardiomyopathy. 4(suppl 6):S50-S57.

Lipoproteins

Watson KE, Horowitz BN, Matson G. Lipid abnormalities in insulin resistant states. 4(4):228-236.

Liver transplantation

Mathur VS. The role of the DA₁ receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. 4(suppl 1):S35-S40.

Long QT syndrome

Riaz K, McCullough PA. Fatal case of delayed repolarization due to cocaine abuse and global ischemia. 4(1):47-53.

Low molecular weight heparin

Young JJ, Kereiakes DJ. Pharmacologic reperfusion strategies for the treatment of ST-segment elevation myocardial infarction. 4(4):216-227.

Low osmolal contrast

Brinker J. What every cardiologist should know about intravascular contrast. 4(suppl 5):S19-S27.

Lox

Shah PK. Does the lysyl oxidase gene *Lox* play a critical role in cardiovascular disease? [Literature Review]. 4(2):121.

Lyse-and-wait

Cynamon J, Pierpont CE. Thrombolysis for the treatment of thrombosed hemodialysis access grafts. 3(suppl 2):S84-S91.

Macrophage immunoreactivity

Best of TCT 2003 [Meeting Review]. 4(4):237-249.

MAGIC Trial

Gersh BJ. Results from the magnesium in coronaries trial [Meeting Review]. 4(4):250-254.

Magnesium

Gersh BJ. Results from the magnesium in coronaries trial [Meeting Review]. 4(4):250-254.

May-Thurner syndrome

Meissner MH. Thrombolytic therapy for acute deep vein thrombosis and the venous registry. 3(suppl 2):S53-S60.

Metabolic syndrome

Watson KE, Horowitz BN, Matson G. Lipid abnormalities in insulin resistant states. 4(4):228-236.

Microalbuminuria

McCullough PA. Beyond serum creatinine: defining the patient with renal insufficiency and why? 4(suppl 1):S2-S6.

McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. 4(suppl 5):S3-S9.

MIRACLE

Abraham WT. Cardiac resynchronization therapy: a review of clinical trials and criteria for identifying the appropriate patient. 4(suppl 2):S30-S37.

Mitral valve

Yoerger DM, Weyman AE. Hypertrophic obstructive cardiomyopathy: mechanism of obstruction and response to therapy. 4(4):199-215.

M-mode echocardiography

Naqvi TZ. Diastolic function assessment incorporating new techniques in Doppler echocardiography. 4(2):81-99.

MUSTIC

Abraham WT. Cardiac resynchronization therapy: a review of clinical trials and criteria for identifying the appropriate patient. 4(suppl 2):S30-S37.

Mycotic aortic aneurysm

Kirkpatrick JN, Ring M, Lang RM. Expanding the differential diagnosis of hemoptysis: mycotic aortic aneurysms. 4(3):180-183.

Myoblasts

Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.

Myocardial infarction

Abraham WT. Diabetes, hypertension, and renal insufficiency in post-myocardial infarction cardiovascular risk. 4(suppl 3):S30-S36.

Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.

Borrello F, Beahan M, Klein L, Gheorghiadu M. Reappraisal of β -blocker therapy in the acute and chronic post-myocardial infarction period. 4(suppl 3):S13-S24.

Cannon CP. Critical pathways for acute myocardial infarction. 4(suppl 3):S47-S53.

Faxon DP. Anticoagulation post-MI: are warfarin and ASA superior to aspirin alone? [Literature Review]. 4(2):121-123.

- Gersh BJ. Results from the magnesium in coronaries trial [Meeting Review]. 4(4): 250-254.
- Jesse RL. Neurohormonal regulation and the overlapping pathology between heart failure and acute coronary syndromes. 4(suppl 4):S29-S36.
- Mazur W, McCracken M, Kereiakes DJ. Coronary calcium and c-reactive protein: another tip of the iceberg [Literature Review]. 4(3):194-196.
- Sackner-Bernstein JD. New evidence from the CAPRICORN trial: the role of carvedilol in high-risk, post-myocardial infarction patients. 4(suppl 3):S25-S29.
- Udelson JE, Patten RD, Konstam MA. New concepts in post-infarction ventricular remodeling. 4(suppl 3):S3-S12.
- Myocardial ischemia**
- Fearon WF, Yeung AC. Evaluating intermediate coronary lesions in the cardiac catheterization laboratory. 4(1):1-7.
- Myocardial reperfusion**
- Young JJ, Kereiakes DJ. Pharmacologic reperfusion strategies for the treatment of ST-segment elevation myocardial infarction. 4(4):216-227.
- Myogenesis**
- Best of TCT 2002 [Meeting Review]. 4(2): 100-106.
- Myoglobin**
- de Lemos JA, Morrow DA. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. 4(suppl 4):S37-S46.
- N-acetylcysteine**
- Lepor NE. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and n-acetylcysteine. 4(suppl 1):S15-S20.
- N-terminal-proBNP**
- McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. 4(suppl 4):S13-S19.
- Natriuretic peptides**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Neovascularity**
- Best of TCT 2003 [Meeting Review]. 4(4): 237-249.
- Nesiritide**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Emerman C. Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy. 4(suppl 7):S13-S20.
- McCullough PA, Joseph K, Mathur VS. Diagnostic and therapeutic utility of b-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. 4(suppl 7):S3-S12.
- Neuro guide catheter**
- Connors JJ. Interventional stroke therapy: the potential benefit of direct intra-arterial infusion. 3(suppl 2):S92-S99.
- Neurohormonal activation**
- Fonarow GC. The management of the diabetic patient with prior cardiovascular events. 4(suppl 6):S38-S49.
- Nonesterified fatty acids**
- Shah A, Shannon RP. Insulin resistance in dilated cardiomyopathy. 4(suppl 6):S50-S57.
- Nonionic agents**
- Brinker J. What every cardiologist should know about intravascular contrast. 4(suppl 5): S19-S27.
- ON-TIME**
- Best of TCT 2003 [Meeting Review]. 4(4): 237-249.
- Operative revascularization**
- Ouriel K. Comparison of surgical and thrombolytic treatment of peripheral arterial disease. 3(suppl 2):S7-S16.
- Osmolality**
- Rudnick MR, Goldfarb S. Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. 4(suppl 5): S28-S33.
- Osmolarity**
- Nikolsky E, Mehran R. Understanding the consequences of contrast-induced nephropathy. 4(suppl 5):S10-S18.
- Osteoporosis**
- Vogel RA. The changing view of hormone replacement therapy. 4(2):68-71.
- Pacing**
- Yoerger DM, Weyman AE. Hypertrophic obstructive cardiomyopathy: mechanism of obstruction and response to therapy. 4(4):199-215.
- Paclitaxel**
- Best of TCT 2002 [Meeting Review]. 4(2): 100-106.
- Best of TCT 2003 [Meeting Review]. 4(4): 237-249.
- Pancreatic beta cells**
- Goldstein BJ. Insulin resistance: from benign to type 2 diabetes mellitus. 4(suppl 6): S3-S10.
- Papillary fibroelastoma**
- Schoondyke JW, Burrell JW, Shabaneh B, et al. Papillary fibroelastoma involving the left ventricular wall. 4(3):184-187.
- Paradoxical coronary embolism**
- Wachsmann DE, Jacobs AK. Paradoxical coronary embolism: a rare cause of acute myocardial infarction. 4(2):107-111.
- Patent foramen ovale**
- Wachsmann DE, Jacobs AK. Paradoxical coronary embolism: a rare cause of acute myocardial infarction. 4(2):107-111.
- Percutaneous coronary intervention**
- Best of TCT 2002 [Meeting Review]. 4(2): 100-106.
- Best of TCT 2003 [Meeting Review]. 4(4): 237-249.
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Nikolsky E, Aymong ED, Dangas G, Mehran R. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. 4(suppl 1): S7-S14.
- Young JJ, Kereiakes DJ. Pharmacologic reperfusion strategies for the treatment of ST-segment elevation myocardial infarction. 4(4):216-227.
- Percutaneous declotting**
- Cynamon J, Pierpont CE. Thrombolysis for the treatment of thrombosed hemodialysis access grafts. 3(suppl 2):S84-S91.
- Percutaneous revascularization**
- Keeley EC, McCullough PA. Coronary revascularization in patients with end-stage renal disease: risks, benefits, and optimal strategies. 4(3):125-130.
- Perioperative arterial disease**
- Sheinbaum R, Ignacio C, Safi HJ, Estrera A. Contemporary strategies to preserve renal function during cardiac and vascular surgery. 4(suppl 1):S21-S28.
- Peripheral arterial disease**
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Doyle J, Creager MA. Pharmacotherapy and behavioral intervention for peripheral arterial disease. 4(1):18-24.
- Ouriel K. Comparison of surgical and thrombolytic treatment of peripheral arterial disease. 3(suppl 2):S7-S16.
- Peripheral arterial occlusion**
- Haskal ZJ. Mechanical thrombectomy devices for the treatment of peripheral arterial occlusions. 3(suppl 2):S45-S52.
- Ouriel K. Safety and efficacy of the various thrombolytic agents. 3(suppl 2):S17-S24.
- Pharmacoeconomics**
- Emerman C. Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy. 4(suppl 7):S13-S20.
- Pharmacomechanical thrombolysis**
- Cynamon J, Pierpont CE. Thrombolysis for the treatment of thrombosed hemodialysis access grafts. 3(suppl 2):S84-S91.
- Phlegmasia cerulea dolens**
- Meissner MH. Thrombolytic therapy for acute deep vein thrombosis and the venous registry. 3(suppl 2):S53-S60.
- Plasminogen activator**
- Bell WR. Therapeutic agents—pharmacokinetics and pharmacodynamics. 3(suppl 2): S34-S44.
- Deitcher SR, Jaff MR. Pharmacologic and clinical characteristics of thrombolytic

- agents. 3(suppl 2):S25-S33.
- Plasminogen-plasmin proteolytic enzyme system**
Bell WR. Therapeutic agents—pharmacokinetics and pharmacodynamics. 3(suppl 2):S34-S44.
- Polytetrafluoroethylene grafts**
Best of TCT 2003 [Meeting Review]. 4(4):237-249.
- Positive end-expiratory pressure**
Mathur VS. The role of the DA₁ receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. 4(suppl 1):S35-S40.
- Postthrombotic syndrome**
Comerota AJ. Quality-of-life improvement using thrombolytic therapy for iliofemoral deep venous thrombosis. 3(suppl 2):S61-S67.
- Power-pulse spray technique**
Best of TCT 2003 [Meeting Review]. 4(4):237-249.
Cynamon J, Pierpont CE. Thrombolysis for the treatment of thrombosed hemodialysis access grafts. 3(suppl 2):S84-S91.
- Premature ventricular complexes**
Prystowsky EN. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator. 4(suppl 2):S47-S54.
- Prophylaxis**
Olin JW. Pulmonary embolism. 3(suppl 2):S68-S75.
- PROSPER**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Pulmonary arteriography**
Olin JW. Pulmonary embolism. 3(suppl 2):S68-S75.
- Pulmonary embolism**
Olin JW. Pulmonary embolism. 3(suppl 2):S68-S75.
- Pulsed-wave Doppler echocardiography**
Naqvi TZ. Diastolic function assessment incorporating new techniques in Doppler echocardiography. 4(2):81-99.
- QRS duration**
Kass DA. Ventricular resynchronization: pathophysiology and identification of responders. 4(suppl 2):S3-S13.
- RACTS**
Best of TCT 2003 [Meeting Review]. 4(4):237-249.
- Radiocontrast nephropathy**
Best of TCT 2002 [Meeting Review]. 4(2):100-106.
Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
Lepor NE. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and n-acetylcysteine. 4(suppl 1):S15-S20.
McCullough PA. Beyond serum creatinine: defining the patient with renal insufficiency and why? 4(suppl 1):S2-S6.
Nikolsky E, Aymong ED, Dangas G, Mehran R. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. 4(suppl 1):S7-S14.
- RAVE**
Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- RAVEL**
Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Renal blood flow**
Lepor NE. A review of pharmacologic interventions to prevent contrast-induced nephropathy. 4(suppl 5):S34-S42.
Nikolsky E, Mehran R. Understanding the consequences of contrast-induced nephropathy. 4(suppl 5):S10-S18.
- Renal failure**
Khanna A, McCullough PA. Malignant hypertension presenting as hemolysis, thrombocytopenia, and renal failure. 4(4):255-259.
Nikolsky E, Aymong ED, Dangas G, Mehran R. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. 4(suppl 1):S7-S14.
- Renal insufficiency**
Lepor NE. The prognostic value of renal function in patients with congestive heart failure and acute myocardial infarction [Literature Review]. 4(3):192-194.
- Renal medulla**
Rudnick MR, Goldfarb S. Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. 4(suppl 5):S28-S33.
- Renin-angiotensin-aldosterone system**
McCullough PA, Joseph K, Mathur VS. Diagnostic and therapeutic utility of b-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. 4(suppl 7):S3-S12.
- Reperfusion**
Gersh BJ. Results from the magnesium in coronaries trial [Meeting Review]. 4(4):250-254.
Katzen BT. Clinical diagnosis and prognosis of acute limb ischemia. 3(suppl 2):S2-S6.
- REPLACE II**
Best of TCT 2003 [Meeting Review]. 4(4):237-249.
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Restenosis**
Best of TCT 2002 [Meeting Review]. 4(2):100-106.
- Revascularization**
Connors JJ. Interventional stroke therapy: the potential benefit of direct intra-arterial infusion. 3(suppl 2):S92-S99.
Holmes DR. Cardiogenic shock: a lethal complication of acute myocardial infarction. 4(3):131-135.
- Roxifiban**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Saphenous vein graft**
Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- SAPPHIRE**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Seizure**
Riaz K, McCullough PA. Fatal case of delayed repolarization due to cocaine abuse and global ischemia. 4(1):47-53.
- Selective dopamine-1 receptor agonist**
Sheinbaum R, Ignacio C, Safi HJ, Estrera A. Contemporary strategies to preserve renal function during cardiac and vascular surgery. 4(suppl 1):S21-S28.
- Septal ablation**
Yoerger DM, Weyman AE. Hypertrophic obstructive cardiomyopathy: mechanism of obstruction and response to therapy. 4(4):199-215.
- Septal myotomy/myectomy**
Yoerger DM, Weyman AE. Hypertrophic obstructive cardiomyopathy: mechanism of obstruction and response to therapy. 4(4):199-215.
- Serum creatinine**
Lepor NE. A review of pharmacologic interventions to prevent contrast-induced nephropathy. 4(suppl 5):S34-S42.
Nikolsky E, Aymong ED, Dangas G, Mehran R. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. 4(suppl 1):S7-S14.
- SIRIUS**
Best of TCT 2003 [Meeting Review]. 4(4):237-249.
Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Sirolimus**
Best of TCT 2002 [Meeting Review]. 4(2):100-106.
Best of TCT 2003 [Meeting Review]. 4(4):237-249.
- Skeletal myoblasts**
Best of TCT 2002 [Meeting Review]. 4(2):100-106.
- SPORTIF III**
Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Statins**
Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
Fonarow GC. The role of in-hospital initia-

- tion of cardiovascular protective therapies to improve treatment rates and clinical outcomes. 4(suppl 3):S37-S46.
- Jacobs AK. Statin therapy and timing [Literature Review]. 4(4):262-263.
- Stents**
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Lepor NE. Clinical impact of stent design [Literature Review]. 4(1):59.
- ST-segment elevation myocardial infarction**
- Holmes DR. Cardiogenic shock: a lethal complication of acute myocardial infarction. 4(3):131-135.
- Young JJ, Kereiakes DJ. Pharmacologic reperfusion strategies for the treatment of ST-segment elevation myocardial infarction. 4(4):216-227.
- Sudden death**
- McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. 4(suppl 4):S13-S19.
- Prystowsky EN. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator. 4(suppl 2):S47-S54.
- Surgery**
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Surgical revascularization**
- Keeley EC, McCullough PA. Coronary revascularization in patients with end-stage renal disease: risks, benefits, and optimal strategies. 4(3):125-130.
- Sympathetic nervous system activation**
- Shah A, Shannon RP. Insulin resistance in dilated cardiomyopathy. 4(suppl 6):S50-S57.
- Syncope**
- Riaz K, McCullough PA. Fatal case of delayed repolarization due to cocaine abuse and global ischemia. 4(1):47-53.
- Systolic blood pressure**
- Holmes DR. Cardiogenic shock: a lethal complication of acute myocardial infarction. 4(3):131-135.
- Systolic dysfunction**
- Francis GS, Tang WHW. Pathophysiology of congestive heart failure. 4(suppl 2):S14-S20.
- Systolic murmur**
- Naqvi TZ, Zaky JW, Raissi SS. Transesophageal echocardiographic evaluation of perioperative systolic murmur in aortic pathology. 4(2):112-116.
- TAXUS II**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- TAXUS IV**
- Best of TCT 2003 [Meeting Review]. 4(4):237-249.
- Tenecteplase**
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Thiazolidinedione**
- Edelman SV. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors. 4(suppl 6):S29-S37.
- Thienopyridines**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Thoracoabdominal aortic aneurysm**
- Sheinbaum R, Ignacio C, Safi HJ, Estrera A. Contemporary strategies to preserve renal function during cardiac and vascular surgery. 4(suppl 1):S21-S28.
- Thrombectomy**
- Haskal ZJ. Mechanical thrombectomy devices for the treatment of peripheral arterial occlusions. 3(suppl 2):S45-S52.
- Thromboatherectomy**
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Thrombocytopenia**
- Khanna A, McCullough PA. Malignant hypertension presenting as hemolysis, thrombocytopenia, and renal failure. 4(4):255-259.
- Thrombolysis**
- Comerota AJ. Quality-of-life improvement using thrombolytic therapy for iliofemoral deep venous thrombosis. 3(suppl 2):S61-S67.
- Cynamon J, Pierpont CE. Thrombolysis for the treatment of thrombosed hemodialysis access grafts. 3(suppl 2):S84-S91.
- Deitcher SR, Jaff MR. Pharmacologic and clinical characteristics of thrombolytic agents. 3(suppl 2):S25-S33.
- Meissner MH. Axillary-subclavian venous thrombosis. 3(suppl 2):S76-S83.
- Thrombolytic agents**
- Bell WR. Therapeutic agents—pharmacokinetics and pharmacodynamics. 3(suppl 2):S34-S44.
- Ouriel K. Safety and efficacy of the various thrombolytic agents. 3(suppl 2):S17-S24.
- Thrombolytic therapy**
- Olin JW. Pulmonary embolism. 3(suppl 2):S68-S75.
- Ouriel K. Comparison of surgical and thrombolytic treatment of peripheral arterial disease. 3(suppl 2):S7-S16.
- Thrombosis**
- Deitcher SR, Jaff MR. Pharmacologic and clinical characteristics of thrombolytic agents. 3(suppl 2):S25-S33.
- Thrombus**
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- TIMI**
- Best of TCT 2003 [Meeting Review]. 4(4):237-249.
- Tissue Doppler imaging**
- Leon AR. Cardiac resynchronization therapy devices: patient management and follow-up strategies. 4(suppl 2):S38-S46.
- Torsade de Pointes**
- Riaz K, McCullough PA. Fatal case of delayed repolarization due to cocaine abuse and global ischemia. 4(1):47-53.
- TRAFFIC**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Transesophageal echocardiography**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Naqvi TZ, Zaky JW, Raissi SS. Transesophageal echocardiographic evaluation of perioperative systolic murmur in aortic pathology. 4(2):112-116.
- Transplantation**
- Nussmeier NA. Improving perioperative outcomes in patients with end-stage heart failure. 4(suppl 1):S29-S34.
- Type 2 diabetes mellitus**
- Goldstein BJ. Insulin resistance: from benign to type 2 diabetes mellitus. 4(suppl 6):S3-S10.
- Upper extremity deep venous thrombosis**
- Meissner MH. Axillary-subclavian venous thrombosis. 3(suppl 2):S76-S83.
- Urogenital atrophy**
- Vogel RA. The changing view of hormone replacement therapy. 4(2):68-71.
- Urokinase**
- Comerota AJ. Quality-of-life improvement using thrombolytic therapy for iliofemoral deep venous thrombosis. 3(suppl 2):S61-S67.
- Vascular endothelial growth factor**
- Best of the ACC Scientific Session 2003 [Meeting Review]. 4(3):150-179.
- Best of the AHA Scientific Sessions 2002 [Meeting Review]. 4(1):25-46.
- Vasoactive therapy**
- Emerman C. Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy. 4(suppl 7):S13-S20.
- Vasomotor stability**
- Vogel RA. The changing view of hormone replacement therapy. 4(2):68-71.
- Venography**
- Leon AR. Practical issues in cardiac resynchronization therapy device implantation. 4(3):142-149.
- Venous stents**
- Meissner MH. Thrombolytic therapy for acute deep vein thrombosis and the venous registry. 3(suppl 2):S53-S60.
- Ventricular fibrillation**
- Prystowsky EN. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator. 4(suppl 2):S47-S54.
- Ventricular tachycardia**
- Prystowsky EN. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator. 4(suppl 2):S47-S54.